Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.86. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | QDTE | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $36.60 |
52-Week Low | $10.24 | $26.85 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QDTE trades at $30.42, up 1.57% with a bearish technical signal from moving averages. The ETF generates weekly dividend income with recent payments ranging from $0.12 to $0.28 per share. Technical indicators show neutral oscillators but bearish momentum with key support at $29 and resistance at $31. Recent media coverage highlights QDTE's high distribution yield strategy through 0DTE covered call options.
The outlook remains cautious given bearish technical signals, though the high-yield distribution strategy appeals to income investors. Key risks include options strategy execution and market volatility affecting premium income. Analyst sentiment appears mixed with some highlighting competitive yield advantages while others note concentration risks in large-cap growth exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
